|
Failure
|
38/125 (30.4)
|
10/16 (62.5)
|
|
On-treatment failure
|
20/125 (16.0)
|
3/16 (18.8)
|
|
Met stopping rule at Week 4/12/24/36
|
13/125 (10.4)
|
0/16
|
|
Other (detectable at EOT)
|
5/125 (4.0)
|
2/16 (12.5)
|
|
Viral breakthrough
|
2/125 (1.6)
|
1/16 (6.3)
|
|
Completed PegIFNα-2a and/or RBV
|
3/125 (2.4)
|
0/16
|
|
Met stopping rule at Week 4/12/24/36
|
1/125 (0.8)
|
0/16
|
|
Other (detectable at EOT)
|
1/125 (0.8)
|
0/16
|
|
Viral breakthrough
|
1/125 (0.8)
|
0/16
|
|
Discontinued PegIFNα-2a and RBV
|
17/125 (13.6)
|
3/16 (18.8)
|
|
Met stopping rule at Week 4/12/24/36
|
12/125 (9.6)
|
0/16
|
|
Other (detectable at EOT)
|
4/125 (3.2)
|
2/16 (12.5)
|
|
Viral breakthrough
|
1/125 (0.8)
|
1/16 (6.3)
|
|
Post-treatment failure
|
18/125 (14.4)
|
7/16 (43.8)
|
|
Viral relapse
|
15/125 (12.0)
|
5/16 (31.3)
|
|
Discontinued PegIFNα-2a and RBV
|
3/125 (2.4)
|
3/16 (18.8)
|
|
Completed PegIFNα-2a and/or RBV
|
12/125 (9.6)
|
2/16 (12.5)
|
|
Missing at time point of SVR12
|
3/125 (2.4)
|
2/16 (12.5)
|
